Literature DB >> 8272408

The interconversion kinetics, equilibrium, and solubilities of the lactone and hydroxyacid forms of the HMG-CoA reductase inhibitor, CI-981.

A S Kearney1, L F Crawford, S C Mehta, G W Radebaugh.   

Abstract

The pH dependence of the interconversion kinetics, equilibrium, and solubilities of the lactone and hydroxyacid forms of the HMG-CoA reductase inhibitor, CI-981 ([R-(R*,R*)]-2-(4-fluorophenyl)- beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl ]- 1H-pyrrole-1-hepatonic acid), are important considerations when choosing and developing one of the forms of these compounds. Over a pH range of 2.1 to 6.0 and at 30 degrees C, the apparent solubility of the sodium salt of CI-981 (i.e., the hydroxyacid form) increases about 60-fold, from 20.4 micrograms/mL to 1.23 mg/mL, and the profile yields a pKa for the terminal carboxyl group of 4.46. In contrast, over a pH range of 2.3 to 7.7 and also at 30 degrees C, the apparent solubility of the lactone form of CI-981 varies little, and the mean solubility is 1.34 (+/- 0.53) micrograms/mL. The kinetics of interconversion and the equilibrium between the hydroxyacid and the lactone forms have been studied as a function of pH, buffer concentration, and temperature at a fixed ionic strength (0.5 M) using a stability-indicating HPLC assay. The acid-catalyzed reaction is reversible, whereas the base-catalyzed reaction can be treated as an irreversible reaction. More specifically, at pH < 6, an equilibrium favoring the hydroxyacid form is established, whereas at pH > 6, the equilibrium reaction is no longer detectable and greatly favors the hydroxyacid form.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8272408     DOI: 10.1023/a:1018923325359

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  7 in total

1.  Equilibrium kinetics of the new experimental anti-tumour compound SK&F 104864-A in aqueous solution.

Authors:  W J Underberg; R M Goossen; B R Smith; J H Beijnen
Journal:  J Pharm Biomed Anal       Date:  1990       Impact factor: 3.935

2.  Hep-G2 cells and primary rat hepatocytes differ in their response to inhibitors of HMG-CoA reductase.

Authors:  M K Shaw; R S Newton; D R Sliskovic; B D Roth; E Ferguson; B R Krause
Journal:  Biochem Biophys Res Commun       Date:  1990-07-31       Impact factor: 3.575

3.  The lactonization of ring-substituted coumarinic acids. Structural effects on the partitioning of tetrahedral intermediates in esterification.

Authors:  R Hershfield; G L Schmir
Journal:  J Am Chem Soc       Date:  1973-10-31       Impact factor: 15.419

4.  Kinetics and mechanisms of lactonization of coumarinic acids and hydrolysis of coumarins. I.

Authors:  E R Garrett; B C Lippold; J B Mielck
Journal:  J Pharm Sci       Date:  1971-03       Impact factor: 3.534

Review 5.  HMG-CoA reductase inhibitors for treatment of hypercholesterolemia.

Authors:  S M Grundy
Journal:  N Engl J Med       Date:  1988-07-07       Impact factor: 91.245

6.  A kinetic and mechanistic study of the hydrolysis of camptothecin and some analogues.

Authors:  J Fassberg; V J Stella
Journal:  J Pharm Sci       Date:  1992-07       Impact factor: 3.534

7.  Inhibitors of cholesterol biosynthesis. 3. Tetrahydro-4-hydroxy-6-[2-(1H-pyrrol-1-yl)ethyl]-2H-pyran-2-one inhibitors of HMG-CoA reductase. 2. Effects of introducing substituents at positions three and four of the pyrrole nucleus.

Authors:  B D Roth; C J Blankley; A W Chucholowski; E Ferguson; M L Hoefle; D F Ortwine; R S Newton; C S Sekerke; D R Sliskovic; C D Stratton
Journal:  J Med Chem       Date:  1991-01       Impact factor: 7.446

  7 in total
  26 in total

Review 1.  Trends in oral drug bioavailability following bariatric surgery: examining the variable extent of impact on exposure of different drug classes.

Authors:  Adam S Darwich; Kathryn Henderson; Angela Burgin; Nicola Ward; Janet Whittam; Basil J Ammori; Darren M Ashcroft; Amin Rostami-Hodjegan
Journal:  Br J Clin Pharmacol       Date:  2012-11       Impact factor: 4.335

2.  Theoretical study of hydrogen bond interactions of fluvastatin with ι-carrageenan and λ-carrageenan.

Authors:  Anastasios G Papadopoulos; Michael P Sigalas
Journal:  J Mol Model       Date:  2010-10-28       Impact factor: 1.810

3.  Efficacy and cytotoxicity in cell culture of novel α-hydroxytropolone inhibitors of hepatitis B virus ribonuclease H.

Authors:  Elena Lomonosova; Jil Daw; Aswin K Garimallaprabhakaran; Nana B Agyemang; Yashkumar Ashani; Ryan P Murelli; John E Tavis
Journal:  Antiviral Res       Date:  2017-06-17       Impact factor: 5.970

4.  Atorvastatin metabolite measurements as a diagnostic tool for statin-induced myopathy.

Authors:  Ine B Skottheim; Martin P Bogsrud; Monica Hermann; Kjetil Retterstøl; Anders Åsberg
Journal:  Mol Diagn Ther       Date:  2011-08-01       Impact factor: 4.074

5.  A hybrid model to evaluate the impact of active uptake transport on hepatic distribution of atorvastatin in rats.

Authors:  Priyanka Kulkarni; Ken Korzekwa; Swati Nagar
Journal:  Xenobiotica       Date:  2019-10-01       Impact factor: 1.908

6.  Surface acidity and solid-state compatibility of excipients with an acid-sensitive API: case study of atorvastatin calcium.

Authors:  Ramprakash Govindarajan; Margaret Landis; Bruno Hancock; Larry A Gatlin; Raj Suryanarayanan; Evgenyi Y Shalaev
Journal:  AAPS PharmSciTech       Date:  2014-10-16       Impact factor: 3.246

7.  Development of a population pharmacokinetic model for atorvastatin acid and its lactone metabolite.

Authors:  Rajesh Narwal; Fatemeh Akhlaghi; Anders Asberg; Monica Hermann; Sara E Rosenbaum
Journal:  Clin Pharmacokinet       Date:  2010-10       Impact factor: 6.447

8.  Atorvastatin up-regulate toxicologically relevant genes in rainbow trout gills.

Authors:  Kathrin Sabine Ellesat; Tor Fredrik Holth; Marcin Włodzimierz Wojewodzic; Ketil Hylland
Journal:  Ecotoxicology       Date:  2012-05-04       Impact factor: 2.823

9.  Toward an in vivo dissolution methodology: a comparison of phosphate and bicarbonate buffers.

Authors:  Jennifer J Sheng; Daniel P McNamara; Gordon L Amidon
Journal:  Mol Pharm       Date:  2009 Jan-Feb       Impact factor: 4.939

10.  GilR, an unusual lactone-forming enzyme involved in gilvocarcin biosynthesis.

Authors:  Madan Kumar Kharel; Pallab Pahari; Hui Lian; Jürgen Rohr
Journal:  Chembiochem       Date:  2009-05-25       Impact factor: 3.164

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.